

## Index

- 5HT (5-hydroxytryptamine)  
 synthesis, 142  
 termination of action, 142–143  
*See also* serotonin.
- 5HT1A receptor partial agonists  
 atypical antipsychotics, 156–159  
 vilazodone, 300–302
- 5HT1B/D receptors  
 effects of atypical antipsychotics,  
 159–160  
 terminal autoreceptors, 159–160
- 5HT2A receptor antagonists, 318  
 atypical antipsychotic actions,  
 142–156  
 effects on dopamine D2 receptors,  
 151–156  
 effects on extrapyramidal  
 symptoms, 150  
 effects on prolactin levels,  
 150–151  
 stimulating downstream dopamine  
 release, 142–150
- 5HT2A receptors  
 blocking downstream dopamine  
 release, 142–150
- 5HT2C receptor antagonists, 313–318  
 fluoxetine, 297
- 5HT2C receptors  
 effects of atypical antipsychotics,  
 159–162  
 role in obesity treatment, 159
- 5HT3 receptor antagonists, 318–322,  
 500, 559
- 5HT3 receptors  
 effects of atypical antipsychotics,  
 162
- 5HT6 receptor antagonists, 500
- 5HT6 receptors  
 effects of atypical antipsychotics,  
 162
- 5HT7 receptors  
 effects of atypical antipsychotics,  
 162–165
- Abeta peptides  
 role in Alzheimer's disease, 505,  
 507, 509
- ABT560, 500
- acamprosate, 385, 417, 556–558
- acetaminophen, 340
- acetylation of histones, 24
- acetylcholine, 5  
 as brain's own nicotine, 543  
 basis for cholinesterase treatment  
 of dementia, 522–528  
 cholinergic pathways, 524  
 cholinergic receptors, 523–528  
 precursors, 524
- acetylcholine transporters, 523
- acetylcholine vesicular transporter, 29
- acetylcholinesterase, 46, 522–525
- Adapin, 342
- adenosine antagonist  
 caffeine, 469
- adiponectin, 565
- adolescents  
 bipolar disorder, 386  
 mania, 386  
 mood stabilizer selection, 386
- affective disorders. *See* mood disorders.
- aggression  
 disorders associated with, 85  
 impulsive–compulsive behavior in  
 psychiatric disorders, 574  
 in schizophrenia, 84
- agomelatine, 159, 313–317, 457
- agonist action  
 G-protein-linked receptors, 35–36  
 ligand-gated ion channels, 56
- agonist spectrum  
 G-protein-linked receptors, 35–43  
 ligand-gated ion channels, 56–64
- agoraphobia  
 in children, 386
- agouti-related peptide, 565
- agouti-related protein, 565
- akathisia, 95, 168
- Akiskal, Hagop, 243
- AKT (kinase enzyme)  
 in schizophrenia, 128
- alcohol dependence, 551–559
- alcoholism treatment, 468
- allodynia, 425
- allosteric modulation  
 ligand-gated ion channels, 65–67
- almorexant (SB649868), 463
- alolia  
 in schizophrenia, 82
- alpha 1 adrenergic antagonists  
 atypical antipsychotics, 173
- alpha 2 antagonists, 317–322
- alpha 2 delta ligands  
 as anxiolytics, 403–405
- alpha 2A adrenergic agonists  
 ADHD treatment, 495–499
- alpha-melanocyte stimulating  
 hormone (alpha-MSH), 565
- alprazolam, 5, 49
- Alzheimer's dementia, 504  
 and psychosis, 79
- Alzheimer's disease  
 acetylcholine as target for current  
 symptomatic treatment, 522–527  
 aggressive and hostile symptoms, 85  
 amyloid as target of disease-  
 modifying treatment, 520–523  
 amyloid cascade hypothesis,  
 505–509  
 basis for cholinesterase treatments,  
 522–528  
 beta amyloid plaques, 505–509  
 beta secretase inhibitors, 522  
 biomarker-enhanced early  
 detection, 521  
 biomarkers, 516–518  
 causes, 503–505  
 cholinergic deficiency hypothesis  
 of amnesia in, 525  
 cholinesterase inhibitors, 525–527  
 clinical features, 503–505  
 cognitive symptoms, 85  
 diagnosis, 503–505  
 diagnostic categories for  
 Alzheimer's dementia, 519–520  
 donepezil, 529  
 galantamine, 527  
 gamma secretase inhibitors,  
 521–522  
 genetic studies, 509  
 glutamate hypothesis of cognitive  
 deficiency, 527–534  
 immunotherapy research, 521  
 memantine, 527–531  
 neurofibrillary tangles, 505–509  
 neuroimaging biomarkers, 517–518  
 pathology, 503–505  
 positive symptoms, 85

## Index

- Alzheimer's disease (cont.)  
 possible Alzheimer's dementia category, 519–520  
 possible benefits of lithium, 372  
 probable Alzheimer's dementia category, 519–520  
 prodromal stage, 515–519  
 range of proposed targets, 533–536  
 risk factors for disease progression, 515  
 risk related to Apo-E, 509–510  
 rivastigmine, 526–527  
 role of Abeta peptides, 505, 507, 509  
 role of amyloid precursor protein (APP), 505–507, 509  
 role of pathological tau, 508  
 search for a vaccine, 521  
 targeting glutamate, 527–531  
 testing of potential treatments, 533–536  
 treatments for psychiatric and behavioral symptoms, 531–533
- Alzheimer's disease stages, 510–511  
 amyloidosis with neurodegeneration and cognitive decline, 519–520  
 amyloidosis with some neurodegeneration, 515–519  
 asymptomatic amyloidosis, 511–515  
 dementia stage, 519–520  
 distinction of MCI from normal aging, 515–519  
 first stage (preclinical), 511–515  
 mild cognitive impairment (MCI), 515–519  
 presymptomatic stage, 511–515  
 second stage, 515–519  
 symptomatic predementia stage, 515–519  
 third (final) stage, 519–520
- amenorrhea, 95  
 amisulpride, 168  
 pharmacologic properties, 212  
 amitifidine (triple reuptake inhibitor), 365  
 amitriptyline, 6, 342  
 amoxapine, 162, 342  
 AMPA PAMs, 228  
 AMPA receptor modulators, 228  
 AMPA receptors, 101–102  
 AMPAkinases, 228, 500  
 amphetamine, 34, 327, 547  
 ADHD treatment, 490–491  
 brain's own (dopamine), 543  
 wake-promoting agent, 468
- amygdala, 122  
 fear response, 392–395  
 neurobiology of fear, 392–395  
 neuroimaging in schizophrenia, 122–126  
 role in fear conditioning, 409–411
- amyloid precursor protein (APP)  
 role in Alzheimer's disease, 505–507, 509
- amyotrophic lateral sclerosis (ALS), 379
- Anafranil, 342
- analgesics  
 interactions with MAOIs, 340
- anandamide, 5, 543, 561
- anatomical basis of neurotransmission, 1–2
- anatomically addressed nervous system, 1–2
- anesthetics  
 interactions with MAOIs, 335
- “angel dust”. *See* phencyclidine (PCP)
- anhedonia  
 in schizophrenia, 82
- anorexia nervosa, 564
- antagonist action  
 G-protein-linked receptors, 36–37  
 ligand-gated ion channels, 57–59
- anticholinergics, 523
- anticonvulsants, 73  
 as mood stabilizers, 373–380
- antidepressant action, 47  
 atypical antipsychotics, 169–172  
 comparison with placebo in clinical trials, 285  
 debate over efficacy, 285–287  
 definition of a treatment response, 285  
 discovery of, 6  
 disease progression in major depression, 289  
 effects throughout the life cycle, 289  
 efficacy in clinical trials, 285–287  
 failure to achieve remission, 287  
 general principles, 285–289  
 goal of sustained remission, 285  
 importance of achieving remission, 289  
 in “real world” trials, 289  
 STAR-D trial of antidepressants, 287
- antidepressant augmenting agents, 346–353  
 brain stimulation techniques, 350–352  
 buspirone, 301–302  
 deep brain stimulation (DBS), 351–352  
 electroconvulsive therapy (ECT), 350  
 L-methylfolate, 346–350  
 psychotherapy as an epigenetic “drug”, 352–353  
 SAME (S-adenosyl-methionine), 350  
 thyroid hormones, 350  
 transcranial magnetic stimulation (TMS), 350–351
- antidepressant classes  
 5HT<sub>2C</sub> antagonism, 313–317  
 alpha 2 antagonists, 317–322  
 circadian rhythm resynchronizer, 313–317  
 melatonergic action, 313–317  
 monoamine oxidase inhibitors (MAOIs), 326–342  
 monoamine transporter blockers, 289–346  
 norepinephrine–dopamine reuptake inhibitors (NDRIs), 309–312  
 selective norepinephrine reuptake inhibitors (NRIs), 312–313  
 serotonin antagonist/reuptake inhibitors (SARIs), 322–326  
 serotonin–norepinephrine reuptake inhibitors (SNRIs), 302–309  
 serotonin partial agonist–reuptake inhibitors (SPARIs), 300–302  
 serotonin selective reuptake inhibitors (SSRIs), 290–300  
 tricyclic antidepressants, 312, 342–346
- antidepressant-induced bipolar disorder, 382
- antidepressant-induced mood disorders, 247–250
- antidepressant “poop-out”, 245
- antidepressant selection  
 arousal combos, 365  
 based on genetic testing, 361–362  
 based on weight of the evidence, 361–362  
 breastfeeding patient, 361  
 California rocket fuel (SNRI plus mirtazapine), 363  
 combination therapies for major depressive disorder, 362–365  
 combination therapies for treatment-resistant depression, 362–365  
 depression treatment strategy, 284–285  
 equipoise situation, 361–362  
 evidence-based selection, 353–354  
 for pregnant patients, 357–361  
 for women based on life-cycle stage, 357  
 for women of childbearing age, 357–361  
 postpartum patient, 361  
 symptom-based approach, 354–357  
 triple action combination (SSRI/SNRI/NDRI), 362–363

- antidepressants in development  
 CRF1 (corticotrophin-releasing factor) antagonists, 365  
 future treatments for mood disorders, 365–366  
 glucocorticoid antagonists, 365  
 multimodal agents, 365–367  
 NMDA blockade, 365–366  
 serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs), 365  
 triple reuptake inhibitors (TRIs), 365  
 vasopressin 1B antagonists, 365
- antihistamines, 335
- antimanic actions  
 atypical antipsychotics, 171
- antipsychotics, 47, 129–130  
 as mood stabilizers, 373–381  
*See also* atypical antipsychotics; conventional antipsychotics.
- antisocial personality disorder, 574  
 aggressive and hostile symptoms, 85
- anxiety disorder treatments, 388  
 alpha 2 delta ligands, 403–405  
 atypical antipsychotics, 171  
 benzodiazepines, 397–403, 414–415  
 buspirone, 405–406  
 generalized anxiety disorder (GAD), 414–415  
 panic disorder, 415–416  
 posttraumatic stress disorder (PTSD), 417–419  
 social anxiety disorder, 416–417
- anxiety disorders, 268, 290, 327, 385  
 blocking reconsolidation of fear memories, 414–415  
 COMT genotypes and vulnerability to worry, 395–397  
 cortico-striatal-thalamic-cortical (CSTC) feedback loops, 395–397  
 fear conditioning, 408–411  
 fear extinction, 411–413  
 fear response, 392–395  
 in children, 386  
 noradrenergic hyperactivity in anxiety, 406–410  
 overlapping symptoms of anxiety disorders, 391–392  
 pain associated with, 427–428  
 pain symptoms, 425  
 painful physical symptoms, 428  
 role of GABA, 397–403  
 role of the amygdala, 392–395  
 serotonin and anxiety, 405–406  
 symptom overlap with major depressive disorder, 389–391  
 symptoms, 388–389  
 worry circuits, 395–397
- anxious self-punishment and blame in depressive psychosis, 80
- apathy  
 in depressive psychosis, 80
- ApoE (apolipoprotein E)  
 and Alzheimer's disease risk, 509–510
- appetite regulation  
 neurobiological basis, 564
- aripiprazole, 49–50, 159, 162, 168–169, 171, 300, 383  
 metabolic risk, 173  
 pharmacologic properties, 202–210
- armodafinil  
 in combinations of mood stabilizers, 385  
 mode of action, 468  
 mood-stabilizing properties, 381
- aromatic amino acid decarboxylase (AAADC), 142
- arousal spectrum, 445
- arson, 85
- asenapine, 48–49, 159, 162, 173  
 metabolic risk, 173  
 pharmacologic properties, 189–190
- Asendin, 342
- asociality  
 in schizophrenia, 82
- aspirin, 340
- atomoxetine, 49, 312  
 ADHD treatment, 493–495
- atorvastatin, 49
- ATPase (adenosine triphosphatase), 31
- atropine, 523
- attention deficit hyperactivity disorder (ADHD), 310, 386, 471  
 age of onset diagnostic criterion, 484  
 aggressive and hostile symptoms, 85  
 and neurodevelopment, 480–487  
 as a disorder of the prefrontal cortex, 471–475  
 as inefficient “tuning” of the prefrontal cortex, 479  
 as norepinephrine and dopamine dysregulation in the prefrontal cortex, 475–479  
 circuits involved in the brain, 471–475  
 comorbidity in adults, 484–487  
 environmental factors, 480  
 executive dysfunction, 471–474  
 impulsive–compulsive dimension, 573  
 impulsivity symptom, 475  
 in adults, 480–487  
 in children and adolescents, 480–487  
 inability to focus, 474  
 inattention symptom, 471–474  
 late-onset type, 484  
 selective inattention symptom, 474  
 symptoms, 471–475
- attention deficit hyperactivity disorder (ADHD) treatment  
 alpha 2A adrenergic agonists, 495–499  
 amphetamine, 490–491  
 atomoxetine, 493–495  
 DAT target for stimulant drugs, 491–496  
 differences in children, adolescents and adults, 484–487  
 future treatments, 500–502  
 general principles of stimulant treatment, 487–490  
 methylphenidate, 490  
 noradrenergic treatment, 493–500  
 slow-release vs fast-release stimulants, 491–496  
 stimulants, 490–493  
 which symptoms to treat first, 487
- atypical antipsychotics, 49–50, 245  
 5HT1A receptor partial agonism, 156–159  
 5HT2A receptor antagonism, 142–156
- anticholinergic actions, 173
- antidepressant actions in bipolar and unipolar depression, 169–172
- antihistamine actions, 174
- antimanic actions, 171
- anxiolytic actions, 171  
 as mood stabilizers, 380–381  
 breastfeeding patient, 386  
 cardiometabolic risk, 173–180  
 characteristic properties, 141–169  
 classification by pharmacologic binding properties, 154–156  
 clinical profile, 141  
 dopamine D2 receptor partial agonism, 165–169  
 effects on 5HT1B/D receptors, 159–160  
 effects on 5HT2C receptors, 159–162  
 effects on 5HT3 receptors, 162  
 effects on 5HT6 receptors, 162  
 effects on 5HT7 receptors, 162–165  
 effects on dopamine D2 receptors, 150–156  
 effects on prolactin levels, 150–151  
 link between receptor-binding properties and clinical actions, 169–173  
 low extrapyramidal symptoms, 150  
 mechanisms of action, 141

## Index

- atypical antipsychotics (cont.)  
 metabolic disease risk, 173–180  
 mitigation of extrapyramidal symptoms, 143–150  
 pharmacologic properties of specific drugs, 180–214  
 pharmacologic properties of the “dones”, 190–202  
 pharmacologic properties of the “pines” (peens), 190  
 pharmacologic properties of “two pips and a rip”, 202–211  
 pharmacological profile, 141  
 relative actions on 5HT<sub>2A</sub> receptors, 154–156  
 relative actions on dopamine D<sub>2</sub> receptors, 154–156  
 sedating actions, 171–173  
 sedative-hypnotic actions, 171–173  
 serotonin–dopamine antagonists, 141  
 therapeutic window, 152–154
- atypical antipsychotics in clinical practice, 213–227  
 integration with psychotherapy, 226–227  
 issues related to switching antipsychotics, 214–220  
 treatment resistance, 221–226  
 violent and aggressive treatment-resistant patients, 221–226
- atypical depression, 245
- auditory hallucinations in schizophrenia, 81
- autism  
 cognitive symptoms, 85  
 autism spectrum disorders  
 impulsive–compulsive dimension, 574
- autoreceptors  
 5HT<sub>1B/D</sub> receptors, 159–160  
 dopamine D<sub>2</sub> receptors, 88  
 on monoamine neurons, 8
- Aventyl, 342
- avoidant personality disorder, 245
- avolition  
 in schizophrenia, 82
- axoaxonic synapses, 1  
 axodendritic synapses, 1  
 axosomatic synapses, 1
- bapineuzumab, 521
- barbiturate addiction, 559
- bariatric surgery, 571
- bath salts as synthetic stimulants, 563
- BDNF (brain-derived neurotrophic factor), 290  
 effects of depression, 313  
 stress effects, 268–269
- behavior  
 influence of gene expression, 22–24
- Belviq (lorcaserin), 571
- Benadryl, 459
- benzodiazepine inverse agonists, 67
- benzodiazepine receptors, 6
- benzodiazepines, 5, 335, 341  
 as anxiolytics, 397–403, 414–415  
 as mood stabilizers, 381, 385  
 as PAMS, 403  
 as positive allosteric modulators (PAMs), 66
- beta endorphin, 5, 565
- beta secretase inhibitors, 522
- BH<sub>4</sub> (tetrahydrobiopterin), 346
- bifeprunox, 168–169
- binge eating disorder, 564
- biomarkers of Alzheimer's disease, 516–518
- bipolar depression, 237–238  
 distinguishing from unipolar depression, 250–252
- bipolar disorder  
 affective symptoms, 85  
 aggressive and hostile symptoms, 85  
 and pregnancy, 385  
 antidepressant induced, 382  
 comorbid with dementia, 250  
 in children and adolescents, 386  
 in perimenopausal women, 385  
 in women, 385–386  
 positive symptoms, 85  
 pregnant patient, 385–386  
 risk in the postpartum period, 385  
 risks with antidepressant treatment, 382  
 treatment-resistant affective symptoms, 85  
*See also* mood stabilizers.
- bipolar disorder NOS (not otherwise specified), 243–244
- bipolar I disorder, 238
- bipolar II disorder, 238
- bipolar spectrum, 243–250  
 and schizoaffective disorder, 243–247  
 bipolar ¼ (0.25) disorder, 245  
 bipolar ½ (0.5) disorder, 243–247  
 bipolar I ½ (1.5) disorder, 248  
 bipolar II ½ (2.5) disorder, 247  
 bipolar III (3.0) disorder, 247–250  
 bipolar III ½ (3.5) disorder, 251  
 bipolar IV (4.0) disorder, 248–252  
 bipolar V (5.0) disorder, 248–250  
 bipolar VI (6.0) disorder, 250  
 schizo-bipolar disorder, 243–247
- bitopertin (RG1678), 232, 234
- BMS-820836 (triple reuptake inhibitor), 365
- body dysmorphic disorder, 575
- borderline personality disorder, 574  
 aggressive and hostile symptoms, 85
- Boston bipolar brew (mood stabilizer combination), 385
- botulinum toxin injections, 442
- brain atrophy and depression, 268–269
- brain stimulation  
 as antidepressant augmentation, 350–352
- breastfeeding  
 prolactin levels during, 95
- breastfeeding patient  
 depression treatment, 361  
 mood stabilizer selection, 386
- brexpiprazole, 159, 162, 165, 169  
 metabolic risk, 173  
 pharmacologic properties, 206–210
- brief psychotic disorder, 79, 245
- brompheniramine, 335
- bulimia, 564
- buprenorphine, 547, 560
- bupropion, 298, 551, 564  
 formulations, 311  
 pharmacologic properties, 309–312
- bupropion/naltrexone (Contrave), 569–571
- buspirone, 159, 346, 405–406, 414  
 augmentation of SSRIs, 301–302
- butyrylcholinesterase, 522–525
- caffeine, 47  
 mode of action, 469  
 wake-promoting agent, 469
- calcineurin, 15
- calcium-calmodulin dependent protein kinases, 16
- calcium channel blockers, 73
- calcium channel blockers (L-type)  
 potential mood stabilizers, 379
- calcium second-messenger actions, 15–17
- California careful cocktail (mood stabilizer combination), 385
- California rocket fuel (SNRI plus mirtazapine), 318, 363
- calmodulin, 16
- cAMP (cyclic adenosine monophosphate), 13–15
- cAMP response element-binding protein (CREB), 16–17
- cancer chemotherapy, 162
- cannabinoid 1 receptor (CB<sub>1</sub>), 6
- cannabinoid CB<sub>1</sub> receptor antagonists, 559

- cannabinoid receptors, 5–6, 556, 561  
 cannabinoids, 442  
 cannabis  
   and schizophrenia, 114  
   effects of, 561  
 carbamazepine, 49–50, 340, 373, 384, 386  
   in combinations of mood stabilizers, 383  
   mood-stabilizing properties, 375–376  
   possible mechanisms of action, 376  
   side effects, 376  
 cardiometabolic risk  
   atypical antipsychotics, 173–180  
 cariprazine, 159, 169  
   metabolic risk, 173  
   pharmacologic properties, 209–210  
 cataplexy  
   GHB treatment, 468  
 catatonic depression, 245  
 cerevastatin, 49  
 cFos gene, 20  
 cGMP (cyclic guanosine monophosphate), 6  
 chemical neurotransmission, 1  
   communication at synapses, 6  
   excitation–secretion coupling, 6, 8–9  
   genome-to-genome communication, 26–27  
   importance in psychopharmacology, 5  
   neurotransmitters, 5–6  
   postsynaptic neuron, 6  
   presynaptic neuron, 6  
   role in psychopharmacology, 26  
   routes, 27  
   sequence, 74–77  
   targets for psychotropic drugs, 27  
   timescale of events, 27  
 chemically addressed nervous system, 5–8  
 childhood psychotic disorders  
   affective symptoms, 85  
   aggressive and hostile symptoms, 85  
   positive symptoms, 85  
 children  
   agoraphobia, 386  
   anxiety disorders, 386  
   bipolar disorder, 386  
   mood-stabilizer selection, 386  
   panic disorder, 386  
   pediatric mania, 386  
 chlormipramine, 342  
 chloral hydrate, 559  
 chlorpheniramine, 335  
 chlorpromazine, 131, 141, 343  
   discovery of antipsychotic effects, 131–132  
   for obsessive–compulsive disorder (OCD), 575  
   for panic disorder, 416  
   for PTSD, 418  
   for social anxiety disorder, 417  
   cognitive remediation psychotherapy, 227  
   cognitive symptoms of schizophrenia, 83–85  
 community treatment programs, 227  
 compulsive eating  
   and obesity, 563–573  
 compulsive hair pulling (trichotillomania), 575  
 compulsive shopping, 575  
 compulsive skin picking, 575  
 compulsivity  
   definition, 537–539  
   *See also* impulsive–compulsive disorders.  
 COMT (catechol-*O*-methyltransferase), 86, 257, 348  
   genetic variants, 348–350  
   genotype and vulnerability to worry, 395–397  
 conceptual disorganization  
   in disorganized/excited psychosis, 80  
 conduct disorder, 386, 574  
 conduct disorders in children  
   aggressive and hostile symptoms, 85  
   constitutive activity  
     G-protein-linked receptors, 35  
 continuum disease model, 245–247  
 Contrave (bupropion/naltrexone), 571  
 conventional antipsychotics  
   ability to cause neuroleptosis, 131–132  
   characteristic properties, 131–141  
   differences in side-effect profiles, 139–141  
   dilemma of blocking D2 receptors in all dopamine pathways, 136–137  
   discovery of chlorpromazine effects, 131–132  
   dopamine D2 receptor antagonism, 132–133  
   drug-induced parkinsonism, 133–136  
   early discoveries, 131  
   extrapyramidal symptoms, 133–136  
   formulations, 141  
   high-potency agents, 141  
   histamine H1 receptor blockade, 139–141  
   hyperprolactinemia, 136  
   list of drugs, 131  
   low-potency agents, 141  
   muscarinic cholinergic receptor blockade, 137–140  
 cholecystokinin, 565  
 cholesterol-lowering drugs  
   drug interactions, 49  
 choline  
   presynaptic transporter, 33  
 cholinergic deficiency hypothesis of amnesia in dementia, 525  
 cholinergic pathways, 524  
 cholinergic receptors, 523–528  
 cholinesterase inhibitors, 525–527  
 chorea, 95  
 chromatin  
   influence on gene expression, 24  
 chronic pain conditions, 420  
   association with psychiatric disorders, 422  
   effects on brain gray matter, 430–432  
   sources of, 420–422  
 chronic pain treatment  
   descending spinal synapses in the dorsal horn, 432–435  
   targeting ancillary symptoms in fibromyalgia, 440–441  
   targeting sensitized circuits, 435–441  
 chronic widespread pain, 428–429  
 circadian rhythms  
   disruption in depression, 313–317  
   effects of melatonergic hypnotics, 457  
   jet lag, 457  
   phase advance, 457  
   phase delay, 457  
 citalopram  
   enantiomers, 299  
   racemic citalopram, 299–300  
   unique properties, 299  
   *See also* escitalopram.  
 cJun gene, 20  
 classical antipsychotics. *See* conventional antipsychotics.  
 clock genes, 313  
 clomipramine, 339–340, 343–344  
 clonidine, 560  
 Clopixol, 131  
 clozapine, 48–50, 84, 156, 162, 171, 173–174, 176, 383  
   metabolic risk, 173  
   pharmacologic properties, 180–182  
 club drugs, 563  
 Coaxil, 342  
 cocaine, 34, 298, 543, 547  
   brain's own (dopamine), 543  
 cocaine and amphetamine regulated transcripts (CART) peptides, 565  
 cocaine vaccine, 547  
 codeine, 49, 335, 340  
 cognitive behavioral therapy, 226, 353  
   for insomnia, 462

## Index

- conventional antipsychotics (cont.)  
 neuroleptosis caused by, 133  
 neuroleptic-induced deficit syndrome, 133  
 prolactin elevation, 136  
 tardive dyskinesia, 133–136
- cortico-accumbens glutamate pathway, 103
- cortico-brainstem glutamate pathway, 103
- cortico-cortical direct glutamate pathway, 106
- cortico-cortical indirect glutamate pathway, 106
- cortico-striatal glutamate pathway, 103
- cortico-striatal-thalamic-cortical (CSTC) feedback loops, 120  
 and anxiety disorders, 395–397
- cortico-thalamic glutamate pathway, 106
- cortisol levels  
 fear response, 394
- cortisol secretion  
 elevation in depression, 313
- CREB transcription factor activation, 16–17
- crenezumab, 521
- CRF1 (corticotrophin-releasing factor) antagonists, 365
- CS717 (AMPAkine), 500
- CTS21666 (beta secretase inhibitor), 522
- curare, 523
- CX1739 (AMPAkine), 500
- CX516 (AMPAkine), 228
- CX546 (AMPAkine), 228
- CX619 (AMPAkine), 228
- cyamemazine, 131
- cyclobenzaprine, 340
- cyclothymic disorder, 238
- CYP450 (cytochrome P450) enzymes  
 and drug interactions, 46–51  
 effects of polymorphisms on drug metabolism, 47  
 number of, 47  
 pharmacokinetic functions, 46–47  
 polymorphism, 47  
 psychotropic drug targets, 46–51  
 role in drug metabolism, 46–47  
 using genotypes to predict drug effects, 361
- CYP450 1A2, 47–48
- CYP450 2C19, 47
- CYP450 2D6, 47–49
- CYP450 2D6 polymorphism  
 effects on metabolism of  
 venlafaxine, 307
- CYP450 3A4, 49–50
- cytokines, 565
- DAO (D-amino acid oxidase), 101, 116
- DAOA (D-amino acid oxidase activator), 101, 116
- DAT. *See* dopamine transporter
- date rape drug  
 gamma hydroxybutyrate (GHB), 468, 563
- deacetylation of histones, 24
- decongestants  
 interactions with MAOIs, 335
- deep brain stimulation (DBS), 351–352
- delusional disorder, 245  
 and psychosis, 79
- delusions, 79  
 in schizophrenia, 81
- dementia  
 affective symptoms, 85  
 aggressive and hostile symptoms, 85  
 basis for cholinesterase treatments, 522–528  
 causes, 503–505  
 cholinergic deficiency hypothesis of  
 amnesia in, 525  
 clinical features, 503–505  
 cognitive symptoms, 85  
 diagnosis, 503–505  
 nondegenerative dementias, 505  
 pathologies, 503–505  
 positive symptoms, 85  
 treatments for psychiatric and  
 behavioral symptoms, 531–533  
 with comorbid bipolarity, 250  
*See also* Alzheimer's disease.
- dementia with Lewy bodies, 504
- demethylation of histones, 24
- Depixol, 131
- Deplin, 346
- depression, 237–238, 245  
 and MAO-A activity, 331  
 and psychosis, 79  
 as prodrome of Alzheimer's disease, 518–519  
 atypical antipsychotics as  
 antidepressants, 169–172  
 benefits of early intervention, 289  
 brain atrophy and stress, 268–269  
 deep brain stimulation (DBS), 351–352  
 disease progression concept, 289  
 disruption of circadian rhythms, 313–317  
 distinguishing unipolar from  
 bipolar depression, 250–252  
 electroconvulsive therapy (ECT), 350  
 in perimenopausal women, 307–308  
 monoamine hypothesis of, 262,  
 289–290  
 monoamine receptor hypothesis  
 and gene expression, 262–269
- neurotransmitter receptor  
 hypothesis, 290–292
- painful physical symptoms, 428
- physiological effects, 313–317
- symptoms and circuits, 273–278
- transcranial magnetic stimulation (TMS), 350–351
- treatment-resistant affective  
 symptoms, 85
- treatment strategy, 284–285
- vulnerability genes, 269–273  
*See also* mood disorders.
- depression treatment  
 postpartum depression, 361  
 pregnant patient, 357–361
- depression with hypomania, 248–250
- depressive psychosis  
 anxious self-punishment  
 and blame, 80  
 apathy, 80  
 psychomotor retardation, 80
- depressive temperament, 238
- Deprimyl, 342
- desensitization  
 ligand-gated ion channels, 64–65
- designer drugs, 562
- desipramine, 162, 312, 342–343
- desvenlafaxine, 48  
 properties, 307–308
- dex-fenfluramine, 573
- dextromethorphan, 335, 339  
 action on NMDA receptors, 366
- DHA (docosahexanoic acid)  
 mood-stabilizing properties, 381
- diabetic ketoacidosis  
 risk with atypical antipsychotics,  
 178–179
- diabetic peripheral neuropathic pain,  
 425
- diagnosis in psychiatry  
 use of Research Domain Criteria, 474
- diazepam, 5
- dichotomous disease model, 243–245
- diethylpropion, 573
- dihydrofolate, 346
- dihydropyridine calcium channel  
 blockers, 73
- diphenhydramine, 459–460
- DISC-1 (disrupted in schizophrenia)  
 gene, 115–121
- disease progression in major  
 depression, 289
- disorganized/excited psychosis  
 conceptual disorganization, 80  
 disorientation, 80  
 excitement, 80
- disorientation  
 in disorganized/excited  
 psychosis, 80

- disulfiram, 559  
 DMT (dimethyltryptamine), 562  
 DNA  
   function of “junk DNA”, 18  
   gene regulatory sections, 18  
   number of genes contained in, 18  
 DNA demethylases, 24  
 DNA methylation, 24  
 DNA methyltransferases (DNMT), 24  
 DNA transcription, 18  
 DNMT1 (DNA methyltransferase 1), 26  
 DNMT2 (DNA methyltransferase 2), 26  
 DNMT3 (DNA methyltransferase 3), 26  
 Dolmatil, 131  
 DOM (2,5-dimethoxy-4-methylamphetamine), 562  
 donepezil, 529  
 “dones”, 154, 162  
   pharmacologic properties, 202  
 dopa decarboxylase, 86, 257  
 dopamine, 5, 237  
   as brain's own cocaine/amphetamine, 543  
   as neurotransmitter of hedonic pleasure, 542–543  
   norepinephrine precursor, 257  
   volume neurotransmission, 8  
 dopamine beta hydroxylase, 257  
 dopamine D2 receptor antagonists  
   conventional antipsychotics, 132–133  
   effects of D2 receptor blockade, 133–137  
 dopamine D2 receptor partial agonists  
   atypical antipsychotics, 165–169  
 dopamine D2 receptors, 86–89  
   effects of atypical antipsychotics, 150–156  
 dopamine hypothesis of  
   schizophrenia, 86, 89–96  
   linking with the NMDA receptor hypofunction hypothesis, 111–113  
 dopamine pathways, 91  
   mesocortical dopamine pathway, 92–94  
   mesolimbic dopamine pathway, 89–92, 94–95  
   nigrostriatal dopamine pathway, 95  
   thalamic dopamine pathway, 96  
   tuberoinfundibular dopamine pathway, 95  
 dopamine receptors, 86–89  
 dopamine reuptake transporter pumps, 8  
 dopamine transporter (DAT), 8, 86  
   psychotropic drug target, 29–32  
   target for stimulants in ADHD, 491–496  
 dopamine vesicular transporter, 29  
 dopaminergic neurons, 86–89  
 DORA 1, 464  
 DORA 5, 464  
 DORA 22, 464  
 DORAs (dual orexin receptor antagonists), 463–464  
 dorsolateral prefrontal cortex (DLPFC), 122  
   in schizophrenia, 122–126  
 dothiapin, 342  
 doxepin, 342, 461  
 doxylamine, 459  
 drug abuse  
   aggressive and hostile symptoms, 85  
   drug abuse treatment, 463  
 drug addiction.  
   *See* impulsive–compulsive disorders; substance addictions.  
 drug-induced parkinsonism, 133–136  
 drug-induced psychosis, 574  
   positive symptoms, 85  
 drug-induced psychotic disorder and psychosis, 79  
 drug interactions  
   and CYP450 enzymes, 46–51  
 drug metabolism  
   role of CYP450 (cytochrome P450) enzymes, 46–47  
 drugs  
   actions on neurotransmission, 5–6  
   similarities to natural neurotransmitters, 5–6  
 drugs of abuse, 339  
   stimulants, 491–492  
 D-serine. *See* serine.  
 DSM (Diagnostic and Statistical Manual), x, 79  
   psychosis, 79  
   Research Domain Criteria, x  
 dual orexin receptor antagonists (DORAs), 463–464  
 duloxetine, 48  
   properties, 308–309  
 dysbindin gene, 115–121  
 dyskinesias, 95  
 dyssocial personality disorder, 574  
 dysthymia, 238  
 dystonia, 95  
 eating disorders, 290, 385, 563  
 “ecstasy” (MDMA), 30, 562  
 edivoxetine  
   norepinephrine reuptake inhibitor (NERI), 313  
 Elavil, 6, 342  
 electroconvulsive therapy (ECT)  
   use in depression, 350  
 EMPA (SORA-2 agent), 464  
 employment  
   help with, 227  
 Endep, 342  
 endocannabinoids (“endogenous marijuana”), 6  
 endophenotypes  
   compulsivity, 539  
   impulsivity, 539  
 endorphins, 559  
   as brain's own morphine/heroin, 543  
 enkephalins, 559  
 enzyme inhibitors, 43–45  
 enzymes  
   irreversible inhibition, 43–45  
   psychotropic drug targets, 43–51  
   reversible inhibition, 43–45  
 EPA (eicosapentanoic acid)  
   mood-stabilizing properties, 381  
 ephedrine, 573  
 epigenetics, 24–26  
   and gene expression, 24  
   and schizophrenia, 114–115  
   definition, 24  
   effects of psychotherapy, 352–353  
   influence on the status quo of a cell, 26  
   molecular mechanisms of gene regulation, 24  
 epistasis, 348–350  
   neuroimaging in schizophrenia, 126–128  
 Epworth Sleepiness Scale, 465  
 ErbB4 gene, 115–121  
 ERK (extracellular signal regulated kinase), 18  
 ERK/AKT signal transduction cascade, 366  
 erythromycin (antibiotic), 49  
 escitalopram  
   unique properties, 300  
 eslicarbazepine  
   potential mood stabilizer, 377–379  
 estrogen replacement therapy (ERT), 307, 361  
 eszopiclone, 341, 453, 455  
 ethchlorvynol, 559  
 ethinamate, 559  
 euthymia, 238  
 excessive daytime sleepiness  
   causes and consequences, 465  
   mechanism of action of wake-promoting agents, 466–469  
   problems with cognitive performance, 465–466

## Index

- excitation–secretion coupling, 6, 8–9  
 excitatory amino acid transporter (EAAT), 96, 101  
 excitatory amino acid transporters 1–5 (EAAT1–5), 33  
 excitement  
   in disorganized/excited psychosis, 80  
 experience-dependent development of synapses, 114–115  
 extrapyramidal nervous system, 95
- family support, 227  
 fear conditioning, 408–411  
   role of the amygdala, 409–411  
 fear extinction, 411–413  
 fear memories  
   blocking reconsolidation of, 414–415  
 fenfluramine, 573  
 fibromyalgia, 425, 428–431  
   milnacipran treatment, 309  
   off-label use of GHB, 468  
   targeting ancillary symptoms, 440–441  
 first-generation antipsychotics.  
   *See* conventional antipsychotics  
 flashbacks, 406  
 flumazenil, 403  
 fluoxetine, 6, 31, 49, 162, 182, 313, 340  
   5HT<sub>2C</sub> antagonist properties, 297  
   combined with olanzapine, 162  
   unique properties, 297  
 flupenthixol, 131  
 fluphenazine, 131  
 fluvastatin, 49  
 fluvoxamine, 48–49  
   sigma 1 receptor binding, 299  
   unique properties, 299  
 fMRI  
   imaging circuits in schizophrenia, 120–126  
 folate, 346, 348, 382  
 food addiction, 563–564  
 Fos protein, 20–21  
 “Foxy” (5-methoxy-diisopropyltryptamine), 562  
 frontotemporal dementia  
   cognitive symptoms, 85
- G-protein-linked receptors  
 activity in absence of agonists, 35  
 agonist action, 35–36  
 agonist spectrum, 35–43  
 antagonist action, 36–37  
 constitutive activity, 35  
 inverse agonist action, 42–43  
 partial agonist action, 37–42  
 pharmacologic subtypes, 35–43  
 psychotropic drug targets, 35–43  
 silent antagonists, 36–37  
 structure and function, 34–35  
 G-protein-linked signal transduction cascades, 11  
 activation of CREB, 16–17  
 influence on gene expression, 16–17  
 phosphoprotein messengers, 13–16  
 second messengers, 11–13  
 G proteins, 17  
 GABA (gamma aminobutyric acid), 5  
 binding to GABA<sub>A</sub> sites, 66  
 effects of benzodiazepines, 66  
 role in anxiety disorders, 397–403  
 synthesis and storage, 397  
 GABA<sub>A</sub> positive allosteric modulators (PAMs), 453  
   and psychiatric insomnia, 455–459  
   insomnia treatment, 454–455  
 GABA receptors, 397–403  
 GABA transaminase, 397  
 GABA transporter (GAT), 397  
 GABA transporters, 33, 397–399  
 GABA vesicular transporter, 34  
 gabapentin, 71, 384–385, 403–405, 414, 437  
   properties, 379  
 galactorrhea, 95  
 galanin, 565  
 galantamine, 524, 527  
 Gamanil, 342  
 gambling disorder, 573  
 gamma hydroxybutyrate (GHB), 563  
 abuse potential, 468  
 date rape drug, 468  
 performance-enhancing drug, 468  
 wake-promoting agent, 468–470  
 gamma secretase inhibitors, 521–522  
 GAT1 transporter, 33  
 gate theory of pain, 425  
 gene effects  
   neuroimaging in schizophrenia, 126–128  
 gene expression  
   and epigenetics, 24  
   consequences of epigenetic influences, 26  
   effects of signal transduction cascades, 16–18  
   functions affected by, 18  
   influence of behavior on, 22–24  
   influence on behavior, 22–24  
   molecular mechanism, 18–24  
   molecular mechanisms of epigenetics, 24  
   regulatory sections of DNA, 18  
   result of neurotransmission, 18–24  
   role of chromatin, 24  
   triggered by phosphoprotein cascade, 16–18  
 gene transcription, 18–20  
 generalized anxiety disorder (GAD), 405  
   treatments, 414–415  
 genes  
   coding region, 18  
   immediate early genes, 20–21  
   late gene activation, 20–22  
   number in the human genome, 18  
   regulatory region, 18–20  
 genetic testing  
   aid to antidepressant selection, 361–362  
 genomes of neurons  
   communication between, 9–10  
 ghrelin, 565  
 glucagon, 565  
 glucocorticoid antagonists, 365  
 glucocorticoid levels  
   effects of stress, 268–269  
 glutamate, 5  
   target in Alzheimer’s disease, 527–531  
 glutamate hypothesis of cognitive deficiency in Alzheimer’s disease, 527–534  
 glutamate pathways  
   cortico-accumbens, 103  
   cortico-brainstem, 103  
   cortico-cortical (direct), 106  
   cortico-cortical (indirect), 106  
   cortico-striatal, 103  
   cortico-thalamic, 106  
   hippocampal-accumbens, 105  
   thalamo-cortical, 106  
 glutamate receptors, 101–102  
   subtypes, 56  
 glutamate synthesis, 96  
 glutamate transporters, 33  
 glutaminase, 96  
 glutamine synthetase, 96  
 glutamine transporter, 96–98  
 glutethimide, 559  
 glycine agonists, 228  
 glycine synthesis, 96–101  
 glycine transporters, 33  
 GlyT1 inhibitors, 232–234  
 grandiose expansiveness  
   in paranoid psychosis, 80  
 GSK (glycogen synthase kinase), 46  
 GSK3 (glycogen synthase kinase 3), 18  
 GSK3 (glycogen synthase kinase 3) inhibitors, 46  
 GSK372475 (triple reuptake inhibitor), 365  
 habits  
   as compulsive behavior, 539–541  
   as conditioned responses, 539–541

- Haldol, 131  
 hallucinations, 79–80  
   in schizophrenia, 81  
 hallucinogen addictions, 561–563  
 haloperidol, 131, 141  
 hedonic pleasure center  
   mesolimbic dopamine pathway,  
   542–543  
 heroin, 559  
   brain's own (endorphins), 543  
 herpes zoster (shingles), 425  
 high-affinity glutamate  
   transporters, 29  
 hippocampal-accumbens glutamate  
   pathway, 105  
 hippocampus  
   dysfunction in schizophrenia, 123  
   effects of stress, 268–269  
 histamine, 5  
   and the sleep/wake switch, 450–453  
   mechanisms of inactivation, 33  
   vesicular transporter, 29  
 histamine H1 receptor antagonists,  
   318  
   as hypnotics, 459–461  
   atypical antipsychotics, 174  
 histamine H1 receptors, 450–451  
   blockade by conventional  
   antipsychotics, 139–141  
 histamine H2 receptors, 452  
 histamine H3 receptor  
   antagonists, 500  
 histamine H3 receptors, 452  
 histamine H4 receptors, 452  
 histamine receptors  
   NMDA receptors, 452  
 histone acetylation, 24  
 histone deacetylases (HDACs), 24, 26  
 histone demethylases, 24  
 histone methylation, 24  
 histone methyltransferases, 24  
 histones deacetylation, 24  
 HIV/AIDS  
   protease inhibitors, 49  
   reverse transcriptase inhibitors, 49  
 HMG-CoA reductase inhibitors, 49  
 hoarding behavior, 575  
 homocysteine, 348  
 hormone-linked signal transduction  
   cascades, 11  
   influence on gene expression, 17  
   phosphoprotein messengers, 16  
   second messengers, 11  
 hormone response elements (HREs), 17  
 hormones, 5  
 hostile belligerence  
   in paranoid psychosis, 80  
 hostile symptoms  
   disorders associated with, 85  
 HPA (hypothalamic-pituitary-  
   adrenal) axis, 365  
   abnormalities in depression, 313  
   abnormalities related to stress, 431  
   effects of stress, 268–269  
   fear response, 394  
 HT0712 (PDE4 inhibitor), 500  
 human genome  
   number of genes, 18  
 Hunter Serotonin Toxicity Criteria, 335  
 hydrocodone, 340, 559  
 hyperalgesia, 425  
 hyperarousal states, 406  
 hyperglycemic hyperosmolar  
   syndrome  
   risk with atypical antipsychotics,  
   178–179  
 hyperkinetic movement disorders, 95  
 hyperprolactinemia, 136, 150–151  
 hypersexual disorder, 573  
 hypersomnia  
   causes and consequences, 465  
   mechanism of action of wake-  
   promoting agents, 466–469  
   problems associated with sleep  
   deprivation, 465  
   problems with cognitive  
   performance, 465–466  
   treatments, 445  
 hyperthymic temperament, 238  
 and mood disorders, 248–252  
 hypochondriasis, 575  
 hypomania, 238  
   antidepressant induced, 382  
   with depression, 248–250  
 hypothalamus  
   role in appetite regulation, 564  
 ICD (International Classification of  
   Diseases), x, 79  
   psychosis, 79  
 iloperidone, 49–50, 159, 162, 173–174,  
   383  
   metabolic risk, 173  
   pharmacologic properties, 197–199  
 imipramine, 162, 342  
 immediate early genes, 20–21  
 impulse control disorders  
   aggressive and hostile symptoms, 85  
 impulsive-compulsive disorders  
   aggression and violence in  
   psychiatric disorders, 574  
   behavior disorders, 573–575  
   bottom-up compulsive dorsal  
   striatal drives, 539–541  
   bottom-up impulsive ventral striatal  
   drives, 539–541  
   compulsion development in drug  
   addiction, 541–542  
 compulsivity endophenotype, 539  
 definition of compulsivity, 537–539  
 definition of impulsivity, 537–539  
 eating disorders, 563–573  
 endophenotypes, 539  
 habit formation, 541–542  
 habits, 539–541  
 hypothetical shared neurobiology,  
   537  
 impulsivity endophenotype, 539  
 mesolimbic dopamine circuit as  
   pathway of reward, 542–543  
 neurocircuitry involved, 539–543  
 obesity as, 563–573  
 obsessive-compulsive disorder  
   (OCD), 574–575  
 range of disorders, 537–538  
 stimulant addiction process,  
   543–547  
 substance addictions, 543–563  
 therapeutic challenge, 537  
 top-down prefrontal cortical  
   inhibition, 539–541  
 ventral to dorsal migration of  
   response, 541–543  
 impulsivity  
   definition, 539  
   in psychiatric conditions, 475  
 inactivation  
   ligand-gated ion channels, 64–65  
 indole-alkylamines, 562  
 inhalants as drugs of abuse, 563  
 inositol  
   mood-stabilizing properties, 381  
 insomnia  
   and slow-wave sleep, 463  
   caused by restless legs syndrome  
   (RLS), 462  
   causes, 452  
   definitions, 452  
 insomnia treatment, 444  
   alpha 2 delta ligands, 462  
   behavioral treatments, 462  
   benzodiazepine hypnotics, 452–455  
   chronic treatment for chronic  
   insomnia, 452–457  
   cognitive behavioral therapy, 462  
   dopamine agonists, 462  
   doxepin, 461  
   dual orexin receptor antagonists  
   (DORAs), 463–464  
   GABA<sub>A</sub> positive allosteric  
   modulators (PAMs), 453–455  
   histamine H1 receptor antagonists  
   as hypnotics, 459–461  
   long-term use of hypnotics,  
   452–453  
   melatonergic hypnotics, 457  
   orexin antagonists, 463–465

## Index

- insomnia treatment (cont.)  
 psychiatric insomnia and  
   GABA<sub>A</sub> PAMs, 455–459  
 serotonergic hypnotics, 457–458  
 single orexin receptor antagonists  
 (SORAs), 463–464  
 sleep hygiene, 462  
 trazodone, 457–458  
 Z-drugs, 453–455
- insulin, 565
- intermittent explosive disorder, 574
- Internet addiction, 573
- interpersonal therapy, 353
- intravenous immunoglobulin (IVIG)  
 Alzheimer's disease trials, 521
- inverse agonist action  
 G-protein-linked receptors, 42–43  
 ligand-gated ion channels, 61–63
- ion-channel-linked receptors, 52–53  
*See also* ligand-gated ion channels.
- ion-channel-linked signal  
 transduction cascades, 11  
 activation of CREB, 16–17  
 influence on gene expression, 16–17  
 phosphoprotein messengers, 13–16  
 second messengers, 11
- ion channels  
 coordination during  
   neurotransmission, 74–77  
 functions of, 52  
 major types, 52  
 psychotropic drug targets, 52  
*See also* ligand-gated ion channels;  
 voltage-gated ion channels.
- ionotropic receptors, 52–53  
*See also* ligand-gated ion channels.
- iproniazid, 326
- isocarboxazid, 327
- jet lag, 457
- JNJ10394049 (SORA-2 agent), 464
- JNJ17305600 (GlyT1 inhibitor), 232
- Jun protein, 20–21
- kainate receptors, 101–102
- ketamine, 67, 107–108, 350, 563  
 antidepressant effects, 365–366
- ketoconazole (antifungal drug), 49
- kinases, 11, 13–18
- kleptomania, 573
- Kraepelin, Emil, 243
- Lami-quel mood-stabilizer  
 combination, 385
- lamotrigine, 341, 383–384, 386  
 in combinations of mood stabilizers,  
 383, 385  
 mechanism of action, 376–377  
 mood-stabilizing properties, 376–377
- rashes caused by, 376  
 tolerability profile, 376
- leptin, 565
- leucine zipper type of transcription  
 factor, 20–21
- levetiracetam, 34, 384
- levodopa, 327
- Lewy body dementia  
 cognitive symptoms, 85
- licarbazepine, 377, 384
- ligand-gated ion channels, 52  
 adaptive states, 64–65  
 agonist spectrum, 56–64  
 allosteric modulation, 65–67  
 AMPA subtype, 56  
 antagonist action, 57–59  
 desensitization, 64–65  
 different receptor states, 64–65  
 full agonist action, 56  
 glutamate receptors, 56  
 inactivation, 64–65  
 inverse agonist action, 61–63  
 negative allosteric modulators  
 (NAMs), 65–67  
 nicotinic cholinergic receptors, 65  
 NMDA subtype, 56  
 partial agonist action, 58–61  
 pentameric subtypes, 54–56  
 positive allosteric modulators  
 (PAMs), 65–67  
 psychotropic drug targets, 54  
 regulation of opening and closing,  
 52–53  
 structure and function, 54–57  
 tetrameric subtypes, 56
- lithium, 46, 339, 346, 386  
 and Alzheimer's disease, 372  
 effects on suicidality, 372  
 for mild mania, 383  
 in combinations of mood stabilizers,  
 383  
 mood-stabilizing properties,  
 371–373  
 plus valproate, 374  
 possible mechanisms of action,  
 371–372  
 side effects, 372–373
- locus coeruleus, 394, 463
- lofepramine, 342
- lorcaserin, 159
- lorcaserin (Belviq), 571
- Loroxyl, 342
- Lou Gehrig's disease, 380
- lovastatin, 49
- low back pain, 425, 431
- loxapine, 131
- Loxitane, 131
- LSD (D-lysergic acid diethylamide),  
 562
- LuAA21004. *See* vortioxetine.
- LuAA24530 (triple reuptake  
 inhibitor), 365
- Ludiomil, 342
- lurasidone, 49–50, 159, 162, 165,  
 381, 383  
 in combinations of mood  
 stabilizers, 385  
 metabolic risk, 173  
 pharmacologic properties, 199–202
- LY2140023 (mGluR presynaptic  
 antagonist/postsynaptic  
 agonist), 228
- LY293558 (AMPAkinase), 228
- LY450139 (semagacestat), 521–522
- LY451395 (AMPAkinase), 500
- major depressive disorder, 165, 238,  
 248  
 affective symptoms, 85  
 as prodrome of Alzheimer's disease,  
 518–519  
 disease progression concept, 289  
 in perimenopausal women, 307–308  
 symptom overlap with anxiety  
 disorders, 389–391  
 use of combination antidepressant  
 therapies, 362–365
- mania, 237–238, 245  
 and psychosis, 79  
 antidepressant induced, 382  
 antimanic actions of atypical  
 antipsychotics, 171  
 in children and adolescents, 386  
 mild mania, 383  
 symptoms and circuits, 278–279  
*See also* mood disorders.
- MAO. *See* monoamine oxidase.
- MAOIs. *See* monoamine oxidase  
 inhibitors.
- MAPK (MAP kinase, mitogen  
 activated protein kinase), 18
- maprotiline, 312, 342–343
- marijuana, 5  
 and schizophrenia, 114  
 brain's own (anandamide), 543  
 effect on appetite, 564  
 effects of, 561
- MC4R agonists, 571
- MDMA (3,4-methylene-  
 dioxymethamphetamine), 30, 562
- meclobemide, 333
- mehylone, 563
- MEK (MAP kinase/ERK kinase or  
 mitogen-activated protein kinase  
 kinase/extracellular signal-  
 regulated kinase kinase), 17
- melancholic depression, 245
- melanin-concentrating hormone, 565

- melanocyte 4 receptors (MC4Rs), 565  
 melatonegic hypnotics, 457  
 melatonin, 457  
 melatonin secretion  
   and depression, 313–317  
 Mellaril, 131  
 memantine, 527–531  
 memory disturbance. *See* dementia.  
 meperidine, 339–340  
 mephedrone, 563  
 mescaline, 562  
 mesolimbic dopamine circuit  
   pathway of reward in  
     impulsive–compulsive disorders,  
     542–543  
 mesoridazine, 131  
 metabolic disease risk  
   atypical antipsychotics, 173–180  
 metabotropic glutamate receptors  
   (mGluRs)  
   presynaptic antagonists/  
   postsynaptic agonists, 228  
 metformin, 571  
 methadone, 340, 560  
 methionine synthase, 348  
 methionine synthase reductase, 348  
 methylation of histones, 24  
 methylenedioxypyrovalerone  
   (MDPV), 563  
 methylenetetrahydrofolate reductase  
   genetic variants, 348–350  
 L-methylfolate, 24, 346–350  
   mood-stabilizing properties, 382  
 methylphenidate, 34, 298, 547  
   ADHD treatment, 490  
   wake-promoting agent, 468  
 methyltransferases, 24  
 methyprylon, 559  
 mianserin, 162, 318–322  
 mild cognitive impairment (MCI)  
   distinction from normal aging,  
   515–519  
 milnacipran  
   properties, 309  
 mirtazapine, 159, 162, 171, 176, 313,  
   318–322, 460  
   California rocket fuel (SNRI plus  
   mirtazapine), 318, 363  
 mitochondria, 257  
 mivacurium, 335  
 mixed state mood disorders, 238, 245  
   antidepressant induced, 382  
 MK-4305 (suvorexant), 463–464  
 MK-6096, 464  
 modafinil  
   mode of action, 466–468  
   mood-stabilizing properties, 381  
 monoamine hypothesis of depression,  
   262, 289–290  
 monoamine neurons  
   volume neurotransmission at  
   autoreceptors, 8  
 monoamine neurotransmitters  
   and mood disorders, 237  
 monoamine oxidase (MAO), 46  
 monoamine oxidase A (MAO-A), 86,  
   142, 257, 327–331  
   and depression, 331  
   reversible inhibitors of MAO-A  
   (RIMAs), 333–335  
 monoamine oxidase B (MAO-B), 86,  
   142, 257, 327–331  
 monoamine oxidase inhibitors  
   (MAOIs), 326–342  
   avoidance of serotonergic agents,  
   335–339  
   clinical management solutions,  
   331–342  
   dietary tyramine interaction,  
   331–335  
   drug–drug interactions, 335–340  
   interactions with analgesics, 340  
   interactions with anesthetics, 335  
   interactions with decongestants,  
   335  
   interactions with opiates, 340  
   interactions with tricyclic  
   antidepressants, 339–340  
 MAO-A activity and depression,  
   331  
 MAO subtypes, 327–331  
 myths and misinformation,  
   331–340  
 reversible inhibitors of MAO-A  
   (RIMAs), 333–335  
 risk of hypertensive crisis, 331–335  
 risk of serotonin toxicity/serotonin  
   syndrome, 335–339  
 switching to and from, 340–342  
 sympathomimetics to avoid or  
   administer with caution, 335  
 monoamine receptor hypothesis of  
   depression  
   and gene expression, 262–269  
 monoamine transporter blockers,  
   289–346  
 monoamine transporters (SLC6  
   family)  
   psychotropic drug targets, 29–32  
 monoamines  
   interactions between, 262  
 mood disorders, 237  
   affective symptoms of  
   schizophrenia, 82–84  
   and hyperthymic temperament,  
   248–252  
   and monoamine neurotransmitters,  
   237  
 bipolar depression, 237–238  
 bipolar disorder NOS (not  
   otherwise specified), 243–244  
 bipolar spectrum, 243–250  
 bipolar ¼ (0.25) disorder, 245  
 bipolar ½ (0.5) disorder, 243–247  
 bipolar I disorder, 238  
 bipolar I ½ (1.5) disorder, 248  
 bipolar II disorder, 238  
 bipolar II ½ (2.5) disorder, 247  
 bipolar III (3.0) disorder, 247–250  
 bipolar III ½ (3.5) disorder, 251  
 bipolar IV (4.0) disorder, 248–252  
 bipolar V (5.0) disorder, 248–250  
 bipolar VI (6.0) disorder, 250  
 bipolarity comorbid with  
   dementia, 250  
 caused by antidepressants, 247–250  
 continuum disease model, 245–247  
 cyclothymic disorder, 238, 247  
 depression, 237–238  
 depression symptoms and circuits,  
   273–278  
 depression with hypomania, 248–250  
 depressive temperament, 238  
 description, 237–238  
 dichotomous disease model, 243–245  
 distinguishing unipolar from  
   bipolar depression, 250–252  
 double depression, 238  
 dysthymia, 238  
 future treatments, 365–366  
 hyperthymic temperament, 238  
 hypomania, 238  
 major depressive disorder, 238, 248  
 mania, 237–238  
 mania symptoms and circuits,  
   278–279  
 mild mania, 383  
 mixed mood state, 238  
 monoamine hypothesis of  
   depression, 262  
 monoamine receptor hypothesis  
   and gene expression, 262–269  
 mood-centered perspective, 244  
 mood chart, 238  
 mood-related temperaments, 238  
 natural history, 252–253  
 neuroimaging, 280–281  
 neurotransmitter systems  
   involved, 255  
 pain associated with, 427–428  
 pain symptoms, 425  
 question of progression, 252–253  
 range of moods, 238  
 rapid cycling, 238  
 related to substance abuse, 251  
 relationship to psychotic disorders,  
   243–247

## Index

- mood disorders (cont.)  
schizoaffective disorder, 243–247  
schizo-bipolar disorder, 243–247  
stress and depression, 268–273  
unipolar depression, 237–238
- mood stabilizer selection, 382–386  
adolescents, 386  
benzodiazepines, 385  
Boston bipolar brew, 385  
breastfeeding patient, 386  
California careful cocktail, 385  
carbamazepine combinations, 383  
children, 386  
combinations of mood stabilizers, 383–385  
first-line treatments in bipolar disorder, 383  
innovative “eminence-based” combinations, 385  
Lami-quel combination, 385  
lamotrigine combinations, 383, 385  
lithium combinations, 383  
monotherapy trials, 382–383  
pregnant patient, 385–386  
quetiapine combinations, 385  
Tennessee mood shine, 385  
valproate combinations, 383  
women and bipolar disorder, 385–386
- mood stabilizers  
anticonvulsants, 373–380  
antipsychotics, 373–381  
armodafinil, 381  
atypical antipsychotics, 380–381  
benzodiazepines, 381  
definitions, 370–371  
future developments, 387  
inositol, 381  
lithium, 371–373  
L-methylfolate, 382  
modafinil, 381  
omega-3 fatty acids (EPA and DHA), 381  
risks related to antidepressants, 382  
thyroid hormones, 382
- morphine, 5, 335  
brain's own (endorphins), 543
- motivational therapies, 227
- motor disturbances in psychosis, 80
- motor hyperactivity, 474
- mRNA, 18
- mTOR (mammalian target of rapamycin) pathway, 366
- multi-infarct dementia  
cognitive symptoms, 85
- muscarine, 523
- muscarinic cholinergic receptors, 137–140  
blockade by conventional antipsychotics, 137–140
- nalmefene, 559
- naloxone, 560
- naltrexone, 385, 417, 547, 556, 560, 564  
bupropion/naltrexone (Contrave), 569–571
- NAMs (negative allosteric modulators), 65–67
- narcolepsy, 463–464  
GHB treatment, 468
- Navane, 131
- nefazodone, 49, 322
- negative allosteric modulators (NAMs), 65–67
- nerve growth factor (NGF), 6
- NET. *See* norepinephrine transporter.
- neuregulin gene, 115–121
- neurodegenerative disorders, 327–329
- neurodevelopment  
and ADHD, 480–487
- neuroimaging  
Alzheimer's disease biomarkers, 517–518  
circuits in schizophrenia, 120–126  
epistasis in schizophrenia, 126–128  
gene effects in schizophrenia, 126–128  
mood disorders, 280–281
- neuroleptic-induced deficit syndrome, 133
- neuroleptic-induced tardive dyskinesia, 95
- neuroleptic malignant syndrome, 136
- neuroleptics, 131–132
- neuron genomes  
communication between, 9–10
- neuronal circuits, 6
- neurons  
autoreceptors, 8  
dysconnectivity in schizophrenia, 114–120  
effects of malfunction, 2  
excitation–secretion coupling, 8–9  
functional alteration by drugs, 2  
general structure of a neuron, 2  
inputs from neuronal circuits, 6  
inputs involving neurotransmitters, 6  
nature of, 1–2  
number in the human brain, 1–2  
synapses, 1
- neuropeptide Y, 565
- neuropeptides, 5  
mechanisms of inactivation, 33
- neurotransmission  
anatomical basis, 1–2  
chemical basis, 5  
classical type, 6  
nonsynaptic diffusion type, 6–8  
retrograde (reverse) type, 6  
signal transduction cascades, 9–24  
target for drug actions, 5–6  
trigger for gene expression, 18–24  
volume type, 6–8  
*See also* chemical neurotransmission.
- neurotransmitter receptor hypothesis  
of depression, 290–292
- neurotransmitter transport  
presynaptic reuptake, 28–29  
sodium pump, 30–31  
vesicular storage, 28–29
- neurotransmitter transporters  
high-affinity glutamate transporters, 29  
intracellular synaptic vesicle transporters, 29–32  
plasma membrane transporters, 29–30  
psychotropic drug targets, 28–34  
SLC1 gene family, 29–30  
SLC6 gene family, 29–30  
sodium/chloride-coupled transporters, 29
- neurotransmitters, 5–6  
as first messengers, 10  
inputs to neurons, 6  
location in synapses, 1  
retrograde neurotransmitters, 6  
similarities of drugs to, 5–6
- neurotrophic factors  
retrograde neurotransmitters, 6
- neurotrophin-linked signal transduction cascades, 11  
influence on gene expression, 17–18  
phosphoprotein messengers, 13–16  
second messengers, 11
- nicotine, 523–524  
brain's own (acetylcholine), 543  
effect on appetite, 564  
effect on nicotinic cholinergic receptors, 65
- nicotine addiction, 311, 547–553
- nicotine dependence, 487
- nicotinic cholinergic receptors, 523–524  
desensitization, 65  
effects of nicotine, 65  
positive allosteric modulators (PAMs), 524
- nicotinic receptor agonists, 500
- nightmares, 406
- nigrostriatal dopamine pathway, 95, 139
- nitric oxide (NO)  
retrograde neurotransmitter, 6
- NMDA antagonists, 442
- NMDA blockade  
potential treatment for mood disorders, 365–366

- NMDA neurotransmission, 232  
 NMDA receptor hypofunction  
   hypothesis of schizophrenia, 107–111  
   linking with the dopamine hypothesis, 111–113  
 NMDA receptors, 99–102, 234  
   negative allosteric modulators (NAMs), 67  
 nonspecific cholinesterase, 522–525  
 nonsteroidal anti-inflammatory drugs, 340  
 nonsynaptic diffusion  
   neurotransmission, 6–8  
 noradrenaline. *See* norepinephrine.  
 noradrenergic hyperactivity in anxiety, 406–410  
 noradrenergic neurons, 255–262  
 norepinephrine, 5, 237  
   regulation of 5HT release, 262  
 norepinephrine dopamine reuptake inhibitors (NDRIs), 309–312  
   in triple action combination (SSRI/SNRI/NDRI), 362–363  
 norepinephrine receptors, 258–262  
 norepinephrine reuptake inhibitors (NERIs)  
   edivoxetine, 313  
   *See also* selective norepinephrine reuptake inhibitors (NRIs).  
 norepinephrine reuptake pump.  
   *See* norepinephrine transporter  
 norepinephrine transporter (NET), 86, 257–258  
   psychotropic drug target, 29–32  
   *See also* SNRIs, 306  
 norepinephrine transporter (NET) inhibition  
   selective NRIs, 312–313  
 norepinephrine vesicular transporter, 29  
 norfluoxetine, 49, 341  
 Norpramin, 342  
 norquetiapine, 183–185  
 nortriptyline, 342–343  
 nucleosomes, 24  
 nucleus accumbens, 542  
 Nuvigil, 468
- obesity  
   and food addiction, 563–564  
   as an impulsive–compulsive disorder, 573  
   neurobiology of appetite regulation, 564  
   role of the hypothalamus in appetite regulation, 564  
 obesity treatment, 566–573  
   bariatric surgery, 571
- bupropion/naltrexone (Contrave), 569–571  
 lorcaserin (Belviq), 571  
 MC4R agonists, 571  
 metformin, 571  
 orlistat, 571  
 phentermine/topiramate ER (Qsmia), 566–569  
   role of 5HT2C receptors, 159  
 tasofensine, 571  
 zonisamide, 571
- obsessive–compulsive disorder (OCD), 299, 346, 574–575  
   cognitive behavioral therapy, 575
- olanzapine, 48, 159, 162, 173–174, 176, 313  
   5HT2C antagonist, 162  
   combined with fluoxetine, 162  
   metabolic risk, 173  
   pharmacologic properties, 182–183
- omega-3 fatty acids (EPA and DHA)  
   mood-stabilizing properties, 381
- OPC4392 (D2 partial agonist), 168
- opiate addictions, 559–561  
 opiate antagonists, 559
- opiates  
   interactions with MAOIs, 340  
   withdrawal syndrome, 560
- opioids  
   interaction with MAOIs, 339  
   oppositional defiant disorder, 574
- Orap, 131
- orbital frontal cortex  
   link with impulsivity, 475
- orexin, 565  
 orexin 1 receptors, 463–464  
 orexin 2 receptors, 463–464  
 orexin A, 463  
 orexin antagonists, 463–465  
 orexin B, 463
- Org 24292 (AMPAkine), 228  
 Org 24448 (AMPAkine), 228  
 Org 25271 (AMPAkine), 228  
 Org 25501 (AMPAkine), 228  
 Org 25573 (AMPAkine), 228  
 Org-25935/SCH-900435 (GlyT1 inhibitor), 232
- orlistat, 571  
 osteoarthritis, 425  
 oxcarbazepine, 340, 384  
   potential mood stabilizer, 377–379
- oxycodone, 559
- pain  
   activation of nociceptive nerve fibers, 422–423  
   allodynia, 425  
   as a psychiatric “vital sign”, 422, 441
- associated with anxiety disorders, 427–428  
 associated with mood disorders, 427–428  
 association with psychiatric disorders, 422  
 central mechanisms in neuropathic pain, 425–428  
 central pain, 421–422  
 definitions, 420  
 definitions of pain states, 421  
 functions of, 420  
 gate theory of pain, 425  
 hyperalgesia, 425  
 in the presence of emotional symptoms, 427–428  
 low back pain treatment, 346  
 neuropathic pain, 423–426  
 nociceptive pathway, 422–423  
 “normal” pain, 423  
 peripheral mechanisms in neuropathic pain, 425  
 peripheral pain, 422  
 psychic pain, 308–309  
 segmental central sensitization, 425  
 somatic pain, 308–309  
 sources of chronic pain conditions, 420–422  
 suprasegmental central sensitization, 425–428, 431  
 “wind-up” response, 425  
   *See also* chronic pain conditions.
- pain syndromes  
   fibromyalgia, 429–430
- pain treatments, 429  
   duloxetine, 308–309  
 paliperidone, 48, 162  
   metabolic risk, 173  
   pharmacologic properties, 194–196
- Pamelor, 342
- PAMs. *See* positive allosteric modulators
- panic attacks, 346, 394, 406, 412  
 treatments, 415–416
- panic disorder, 327, 405  
   in children, 386  
   treatments, 415–416
- paranoid personality disorder, 245  
 paranoid projection  
   in paranoid psychosis, 80
- paranoid psychosis  
   grandiose expansiveness, 80  
   hostile belligerence, 80  
   paranoid projection, 80
- paraphilias, 573
- Parkinson's disease, 95, 167, 351  
   use of MAO-B inhibitors, 327–329
- Parkinsonian dementia  
   cognitive symptoms, 85

## Index

- parkinsonism  
 drug-induced, 133–136
- paroxetine  
 discontinuation reactions, 298–299  
 side effects, 298–299  
 unique properties, 298–299
- partial agonist action  
 G-protein-linked receptors, 37–42  
 ligand-gated ion channels, 58–61
- perceptual distortions in psychosis, 80
- performance-enhancing drug  
 GHB, 468
- perimenopausal women  
 and bipolar disorder, 385  
 effectiveness of SSRIs and SNRIs,  
 307–308  
 treatment of depression, 307–308  
 vasomotor symptoms, 305, 307–308
- Periodic Limb Movement Disorder  
 (PLMD), 462
- perospirone  
 pharmacologic properties, 213
- perphenazine, 131
- Pertofran, 342
- phantom limb pain, 425
- pharmaceutical industry, 286
- pharmacodynamic actions of drugs, 47
- pharmacokinetics, 46–47
- phencyclidine (PCP), 67, 107–108, 563
- phenelzine, 327
- phentermine, 573
- phentermine/topiramate ER (Qsmia),  
 566–569
- phenylalkylamines, 562
- phosphatases, 11, 13–17
- phosphodiesterase 4 (PDE4)  
 inhibitors, 500
- phosphoprotein cascade triggering  
 gene expression, 16–18
- phosphoprotein messengers, 13–16
- Pick's dementia  
 cognitive symptoms, 85
- pimozide, 49, 131
- “pines” (peens), 154, 162  
 pharmacologic properties, 190
- piperidinedione derivatives, 559
- Piportil, 131
- pipothiazine, 131
- placebo effect  
 in antidepressant clinical trials, 285
- plasma membrane neurotransmitter  
 transporters, 29–30
- positive allosteric modulators (PAMs),  
 65–67  
 AMPA PAMs (AMPAkines), 228  
 benzodiazepines, 403
- postmenopausal women  
 effectiveness of SSRIs and  
 SNRIs, 308
- postpartum depression, 245, 361
- postpartum period  
 bipolar disorder risk, 385
- postpartum psychosis, 361
- post-stroke dementia  
 cognitive symptoms, 85
- postsynaptic elements, 1
- postsynaptic neuron, 6
- posttraumatic stress disorder (PTSD),  
 171, 268, 394, 405, 409  
 blocking reconsolidation of fear  
 memories, 414–415  
 painful physical symptoms, 428  
 treatments, 417–419
- pramipexole, 167, 385
- pravastatin, 49
- prazocin, 407
- PRC200-SS (triple reuptake inhibitor),  
 365
- prefrontal cortex  
 and ADHD, 471–479  
 volume neurotransmission of  
 dopamine, 8
- pregabalin, 71, 384–385, 403–405, 414,  
 437  
 properties, 379
- pregnancy  
 and bipolar disorder, 385–386  
 environmental factors in ADHD,  
 480  
 treatment of depression,  
 357–361  
 use of mood stabilizers, 385–386
- premenstrual dysphoric disorder, 290
- presynaptic elements, 1
- presynaptic neuron, 6
- pro-apoptotic actions, 46
- prolactin  
 effects of atypical antipsychotics,  
 150–151  
 effects of elevated levels, 95
- Prolixin, 131
- pro-opiomelanocortin (POMC)  
 neurons, 565
- protease inhibitors (for HIV/AIDS),  
 49
- protein kinase A, 16
- Prothiaden, 342
- proton pump mechanism  
 vesicular neurotransmitter  
 transport, 34
- protriptyline, 342–343
- Prozac (fluoxetine), 6
- PRX03140 (5HT6 antagonist), 500
- PRX07034 (5HT6 antagonist), 500
- pseudobulbar affect, 366
- pseudocholinesterase, 522–525
- psilocybin, 562
- psychedelic hallucinations, 561
- psychiatric “vital signs”
- pain, 422, 441  
 sleep, 444
- psychiatric disorders  
 consequences of epigenetic  
 influences, 26  
 impulsive–compulsive aggression  
 and violence, 574
- psychiatric insomnia  
 and GABA<sub>A</sub> PAMs, 455–459
- psychomimetic hallucinations, 561
- psychomotor retardation  
 in depressive psychosis, 80
- psychopathology  
 dimensions of, x–xi
- psychopathy, 574
- psychopharmacology  
 influencing abnormal  
 neurotransmission, 6  
 targets within signal transduction  
 cascades, 11
- psychosis  
 clinical description, 79  
 depressive psychosis, 80  
 difficulty of definition, 79  
 disorders associated with, 79  
 disorders defined by, 79  
 disorganized/excited psychosis, 80  
 motor disturbances, 80  
 nature of behavioral disturbances,  
 79–80  
 paranoid psychosis, 80  
 perceptual distortions, 80  
 types of, 79
- psychotherapy  
 as an epigenetic “drug”, 352–353  
 combined with antidepressants,  
 352–353  
 role in schizophrenia treatment,  
 226–227
- psychotic depression, 245  
 affective symptoms, 85  
 positive symptoms, 85
- psychotic disorder due to a medical  
 condition, 79
- psychotic disorders  
 relationship to mood disorders,  
 243–247
- psychotropic drug metabolism  
 role of CYP450 (cytochrome P450)  
 enzymes, 46–47
- psychotropic drug targets  
 cytochrome P450 enzymes, 46–51  
 enzymes, 43–51  
 G-protein-linked receptors,  
 35–43  
 ligand-gated ion channels, 54  
 monoamine transporters (SLC6  
 family), 29–32

- neurotransmitter transporters, 28–34  
 range of targets, 28  
 sites of action, 28  
 vesicular transporters (SLC18 gene family), 34  
 pyromania, 573
- Qsmia (phentermine/topiramate ER), 566–569
- quetiapine, 49–50, 156, 159, 162, 171, 173–174, 176, 300, 313, 381, 383, 460  
 effects at different doses, 185–189  
 effects in different formulations, 185  
 in combinations of mood stabilizers, 385  
 metabolic risk, 173  
 pharmacologic properties, 183–189  
 quinidine, 366
- racemic citalopram, 299  
 radafaxine, 310  
 Raf (kinase), 17  
 ramelteon, 453, 457  
 rapacuronium, 335  
 rapid cycling in mood disorders, 238  
 antidepressant induced, 382
- Ras protein, 17  
 rasagiline, 327  
 reboxetine, 312  
 recurrent thoughts, 395  
 Research Domain Criteria  
 in DSM, x  
 use for diagnosis, 474
- reserpine, 34  
 restless legs syndrome (RLS), 462  
 retrograde (reverse)  
 neurotransmission, 6
- reverse transcriptase inhibitors (for HIV/AIDS), 49  
 reversible inhibitors of MAO-A (RIMAs), 333–335
- reward pathway  
 mesolimbic dopamine circuit, 94–95, 542–543
- RG1678 (bitopertin), 232, 234  
 RG3487 (acetylcholine booster), 500
- rifampin, 49  
 riluzole, 384  
 properties, 379–380
- rimonabant, 556, 561  
 risperidone, 48, 162, 171, 173, 385  
 metabolic risk, 173  
 pharmacologic properties, 190–194  
*See also* paliperidone.
- rivastigmine, 526–527
- RNA polymerase, 18–20  
 RNA translation, 20
- ropinirole, 167, 385  
 RSG4 gene, 116  
 RSK (ribosomal S6 kinase), 18
- SAM-315 (5HT<sub>6</sub> antagonist), 500  
 SAM-531 (5HT<sub>6</sub> antagonist), 500  
 SAMe (S-adenosyl-methionine), 24, 350
- sarcosine (GlyT1 inhibitor), 232, 234  
 SB334867 (SORA-1 agent), 464  
 SB408124 (SORA-1 agent), 464  
 SB410220 (SORA-1 agent), 464  
 SB649868 (almorexant), 463  
 SB674042 (SORA-1 agent), 464  
 SB742457 (5HT<sub>6</sub> antagonist), 500  
 SCH 1381252 (beta secretase inhibitor), 522
- schizoaffective disorder, 243–247  
 affective symptoms, 85  
 and psychosis, 79  
 positive symptoms, 85
- schizobipolar disorder, 243–247  
 schizoid personality disorder, 245  
 schizophrenia, 85  
 amygdala neuroimaging, 122–126  
 and psychosis, 79  
 brain circuits and symptom dimensions, 85–86  
 cardiovascular disease risk, 80–81  
 definition, 81  
 direct and indirect costs  
 in the US, 81  
 dopamine hypothesis of, 86, 89–96  
 dorsolateral prefrontal cortex (DLPFC) neuroimaging, 122–126  
 dysconnectivity genes, 115–116  
 dysconnectivity of neurons, 114–120  
 environmental factors, 114–120  
 genetic risk factors, 114–120  
 hippocampal dysfunction, 123  
 incidence, 80  
 influence of epigenetics, 114–115  
 life expectancy of patients, 80–81  
 linking NMDA receptor hypofunction and dopamine hypotheses, 111–114  
 mortality rate, 80–81  
 neurodevelopmental factors, 114–120  
 neuroimaging circuits, 120–126  
 neuroimaging epistasis, 126–128  
 neuroimaging of gene effects, 126–128  
 neurotransmitters and pathways involved, 86–114
- NMDA receptor hypofunction  
 hypothesis of, 107–111  
 relationship to mood disorders, 243–247  
 risk genes, 115–116  
 suicide risk, 80–81  
 susceptibility genes, 114–120  
 treatment-resistant affective symptoms, 85  
 ventromedial prefrontal cortex (VMPFC) neuroimaging, 122–126
- schizophrenia and dopamine, 86–96  
 dopaminergic neurons, 86–89  
 key dopamine pathways in the brain, 91  
 mesocortical dopamine pathway and affective symptoms, 92–94  
 mesocortical dopamine pathway and cognitive symptoms, 92–94  
 mesocortical dopamine pathway and negative symptoms, 92–94  
 mesolimbic dopamine pathway and negative symptoms, 94–95  
 mesolimbic dopamine pathway and positive symptoms, 89–92  
 mesolimbic dopamine pathway and reward, 94–95  
 nigrostriatal dopamine pathway, 95  
 thalamic dopamine pathway, 96  
 tuberoinfundibular dopamine pathway, 95
- schizophrenia and glutamate, 96–111  
 faulty NMDA synapses on GABA interneurons in prefrontal cortex, 107–111  
 glutamate receptors, 101–102  
 glutamate synthesis, 96  
 key glutamate pathways in the brain, 102–106  
 synthesis of D-serine, 96–101  
 synthesis of glutamate co-transmitters, 96–101  
 synthesis of glycine, 96–101
- schizophrenia future treatments, 227–235  
 AMPA/kines, 228  
 glycine agonists, 228  
 GlyT1 inhibitors, 232–234  
 mGluR presynaptic antagonists/postsynaptic agonists, 228  
 presymptomatic treatments, 235  
 prodromal treatments, 235  
 selective glycine reuptake inhibitors (SGRIs), 232–234  
 targeting cognitive symptoms, 235
- schizophrenia symptoms  
 affective blunting or flattening, 82  
 affective symptoms, 83–84

## Index

- schizophrenia symptoms (cont.)  
 aggressive symptoms, 84  
 alogia, 82  
 anhedonia, 82  
 asociality, 82  
 assessment of negative symptoms, 82  
 auditory hallucinations, 81  
 avolition, 82  
 cognitive symptoms, 83–85  
 delusions, 81  
 hallucinations, 81  
 in other disorders, 85  
 negative symptoms, 81–83, 113–114  
 positive symptoms, 81, 111–113  
 prodromal negative symptoms, 83  
 subcategories by symptom dimensions, 83–85  
 treatment, 83
- schizophrenia treatment  
 early discoveries of antipsychotic drugs, 131  
 psychotherapy and atypical antipsychotics, 226–227  
*See also* antipsychotics; atypical antipsychotics; conventional antipsychotics.
- schizophreniform disorder, 245  
 and psychosis, 79
- schizotypal personality disorder, 245
- scopolamine, 350, 523
- seasonal affective disorder, 245
- second-generation antipsychotics.  
*See* atypical antipsychotics.
- second-messenger formation, 11–13
- sedating actions  
 atypical antipsychotics, 171–173
- sedative hypnotic actions  
 atypical antipsychotics, 171–173
- sedative hypnotics  
 addiction to, 559
- selective glycine reuptake inhibitors (SGRIs), 101, 232–234, 413
- selective melatonin agonists, 457
- selective norepinephrine reuptake inhibitors (NRIs)  
 atomoxetine, 312  
 reboxetine, 312
- selegiline, 327, 333
- self-injurious behaviors, 85
- Selinco, 559
- semagacestat (LY450139), 521–522
- SEP-225289 (triple reuptake inhibitor), 365
- Serentil, 131
- serine hydroxymethyltransferase (SHMT), 101
- D-serine synthesis, 96–101
- D-serine transporter (D-SER-T), 101
- L-serine transporter (SER-T), 101
- serotonergic hypnotics, 457–458
- serotonin, 5, 237  
 and anxiety, 405–406  
 synthesis, 142  
 termination of action, 142–143  
*See also* 5HT (5-hydroxytryptamine).
- serotonin antagonist/reuptake inhibitors (SARIs), 322–326
- serotonin norepinephrine dopamine reuptake inhibitors (SNDRIs), 365
- serotonin norepinephrine reuptake inhibitors (SNRIs), 302–309, 405  
 California rocket fuel (SNRI plus mirtazapine), 363  
 desvenlafaxine, 307–308  
 dopamine increase in the prefrontal cortex, 305–306  
 duloxetine, 308–309  
 effectiveness in postmenopausal women, 308  
 effects of NET inhibition, 305–306  
 in triple action combination (SSRI/SNRI/NDRI), 362–363  
 milnacipran, 309  
 venlafaxine, 306–307
- serotonin partial agonist reuptake inhibitors (SPARIs)  
 vilazodone, 300–302
- serotonin selective reuptake inhibitors (SSRIs), 290–300, 405  
 citalopram, 299  
 common features, 291–296  
 discontinuation reactions, 298–299  
 effectiveness in postmenopausal women, 308  
 escitalopram, 300  
 fluoxetine, 297  
 fluvoxamine, 299  
 in triple action combination (SSRI/SNRI/NDRI), 362–363  
 paroxetine, 298–299  
 SERT blockade, 291–296  
 sertraline, 297–298  
 unique properties of individual SSRIs, 296–300
- serotonin toxicity/serotonin syndrome  
 risk with MAOIs, 335–339
- serotonin transporter (SERT), 6, 142  
 blockade by SSRIs, 291–296  
 psychotropic drug target, 29–32
- serotonin vesicular transporter, 29
- SERT. *See* serotonin transporter.
- sertindole, 49–50  
 pharmacologic properties, 215
- sertraline  
 dopamine receptor (DAT) inhibition, 297–298  
 sigma 1 receptor binding, 297–298  
 unique properties, 297–298
- setipitilene, 318
- sexual acting out, 85
- sexual dysfunction, 95
- shared psychotic disorder, 245
- sibutramine, 573
- sigma 1 receptor binding  
 fluvoxamine, 299  
 sertraline, 297–298
- signal transduction cascades, 9–24  
 activation of CREB transcription factor, 16–17  
 forming a second messenger, 11–13  
 G-protein-linked systems, 11  
 hormone-linked systems, 11  
 ion-channel-linked systems, 11  
 kinases, 11, 13–18  
 molecular mechanism of gene expression, 18–24  
 neurotransmission trigger for gene expression, 18–24  
 neurotransmitter first messengers, 10  
 neurotrophin-linked systems, 11  
 phosphatases, 11, 13–17  
 phosphoprotein cascade triggering gene expression, 16–18  
 phosphoprotein messengers, 13–16  
 potential targets for psychotropic drugs, 11  
 range of genes targeted by, 18  
 sequence of messengers, 10–11  
 targets, 13  
 types of, 11
- silent antagonist drug action, 36–37
- simvastatin, 49
- Sinequan, 342
- single orexin receptor antagonists (SORAs), 463–464
- SLC1 gene family transporters, 29, 33
- SLC6 gene family transporters, 29, 33  
 monoamine transporters, 32
- SLC17 gene family transporters, 29, 34
- SLC18 gene family transporters, 29, 34
- SLC18 gene family vesicular transporters  
 psychotropic drug targets, 34
- SLC32 gene family transporters, 29, 34
- sleep  
 as a psychiatric “vital sign”, 444  
 effects of slow-wave sleep, 463
- sleep and wakefulness  
 arousal spectrum, 445  
 role of histamine, 450–453  
 sleep/wake switch, 445–453

- sleep deprivation, 350  
 problems associated with, 465
- sleepiness  
 causes and consequences, 465  
 mechanism of action of wake-promoting agents, 466–469  
 problems associated with sleep deprivation, 465  
 problems with cognitive performance, 465–466
- slow-wave sleep  
 effects of, 463
- smoking  
 effect on CYP450 1A2, 48
- social anxiety disorder, 405  
 treatments, 416–417
- social phobia, 327
- sodium/chloride-coupled transporters, 29
- sodium oxybate  
 wake-promoting agent, 468–470
- sodium potassium ATPase (adenosine triphosphatase), 31
- sodium pump, 30–31
- solanezumab, 521
- solute carrier gene families. *See SLC gene families.*
- somatization, 575
- SORA-1 agents, 464
- SORA-2 agents, 464
- SORAs (single orexin receptor antagonists), 463–464
- specific neutral amino acid transporter (SNAT), 96–98, 100
- SSR 241586 (GlyT1 inhibitor), 232
- SSR 504734 (GlyT1 inhibitor), 232
- SSRIs. *See* serotonin selective reuptake inhibitors.
- Stablon, 342
- STAR-D trial of antidepressants, 287
- statins  
 drug interactions, 49
- Stelazine, 131
- stereotyped behaviors  
 impulsive–compulsive dimension, 574
- stereotyped movement disorders  
 impulsive–compulsive dimension, 574
- Sternbach criteria for serotonin toxicity, 335
- Stevens–Johnson Syndrome, 376
- stimulants, 468  
 ADHD treatment, 487–493  
 effects on appetite, 564  
 use as drugs of abuse, 491–492
- stress, 365  
 and depression vulnerability genes, 269–273  
 and vulnerability to depression, 273  
 BDNF effects, 268–269  
 brain atrophy and depression, 268–269  
 effects of environmental stress, 273  
 effects on glucocorticoid levels, 268–269  
 effects on the hippocampus, 268–269  
 effects on the HPA (hypothalamic-pituitary-adrenal) axis, 268–269  
 stress sensitization of brain circuits, 409
- substance abuse  
 mood disorders related to, 251
- substance addictions, 543–563  
 alcohol dependence, 551–559  
 and the mesolimbic dopamine reward pathway, 542–543  
 barbiturates, 559  
 bath salts as synthetic stimulants, 563  
 club drugs, 563  
 development of compulsions, 541–542  
 hallucinogens, 561–563  
 inhalants, 563  
 marijuana, 561  
 nicotine, 547–553  
 opiate addictions, 559–561  
 sedative hypnotics, 559  
 stimulant addiction process, 543–547  
 toluene, 563
- substance-induced psychotic disorder and psychosis, 79
- substance use disorders, 385
- subsyndromal/ultra-high-risk psychosis prodrome, 245
- suicidality  
 antidepressant induced, 382  
 effects of lithium, 372
- suicide, 85  
 in adolescents, 386
- sulpiride, 131, 168  
 pharmacologic properties, 211
- supplementary motor area, 474
- suprachiasmatic nucleus (SCN), 313–317, 457
- Surmontil, 342
- suvorexant (MK-4305), 463–464
- SV2A transporter, 34
- symptom endophenotypes, x–xi
- SYN114 (5HT6 antagonist), 500
- SYN120 (5HT6 antagonist), 500
- synapses, 1  
 asymmetric type, 1  
 axoaxonic type, 1  
 axodendritic type, 1  
 axosomatic type, 1
- chemical neurotransmission  
 process, 6  
 direction of communication, 1  
 dysconnectivity genes, 115–116  
 experience-dependent development, 114–115  
 location of, 1  
 location of neurotransmitter, 1  
 number in the human brain, 1–2  
 postsynaptic elements, 1  
 presynaptic elements, 1  
 synaptic vesicle transporters, 29–32
- tapentadol, 340
- tardive dyskinesia, 95
- tasimelteon, 457
- tasofensine, 365, 571
- temper dysregulation, 386
- temperaments  
 mood-related, 238
- Tennessee mood shine (mood-stabilizer combination), 385
- Tercian, 131
- terminal autoreceptors  
 5HT1B/D receptors, 159–160
- tetrabenazine, 34
- tetrahydrobiopterin (BH4), 346
- thalamo-cortical glutamate pathway, 106
- THC (delta-9-tetrahydrocannabinol), 561
- theophyllin, 48
- therapeutic window  
 atypical antipsychotics, 152–154
- thioridazine, 131
- thioridazone, 49
- thiothixene, 131
- Thorazine, 131
- thyroid hormones, 385  
 as antidepressant augmenting agents, 350  
 possible mood-stabilizing effect, 382
- tiagabine, 33
- tianeptine, 342
- tic disorders, 95  
 impulsive–compulsive dimension, 574
- Tofranil, 342
- toluene, 563
- topiramate, 384–385, 559, 564  
 properties, 379
- Tourette's syndrome  
 impulsive–compulsive dimension, 574
- toxic epidermal necrolysis, 376
- tramadol, 339–340
- transcranial magnetic stimulation (TMS), 350–351

## Index

- transcription factors, 18–20  
 leucine zipper type, 20–21  
 tranylcypromine, 327  
 trazodone, 322–326, 341, 453  
 insomnia treatment, 457–458  
 trial-based therapy, 353  
 triazolam, 49  
 trichotillomania (compulsive hair pulling), 575  
 tricyclic antidepressants, 49, 159, 312, 342–346  
 antihistamine properties, 460  
 interactions with MAOIs, 339–340  
 potential for death in overdose, 343–346  
 side effects, 343–346  
 trifluoperazine, 131  
 Trilafon, 131  
 trimipramine, 342  
 triple reuptake inhibitors (TRIs), 365  
 TriRima (CX157), 335  
 Trypizol, 342  
 tryptophan, 142  
 tryptophan hydroxylase, 142, 346  
 tuberoinfundibular dopamine pathway, 95  
 tuberomammillary nucleus, 452, 463  
 “two pips and a rip”, 154, 162  
 pharmacologic properties, 211  
 type 2 diabetes  
 Alzheimer’s disease risk factor, 515  
 typical antipsychotics.  
*See* conventional antipsychotics.  
 tyramine in the diet  
 interaction with MAOIs, 331–335  
 tyrosine, 86, 257  
 tyrosine hydroxylase, 86, 257, 346  
 tyrosine pump (transporter), 86
- unipolar depression, 237–238  
 distinguishing from bipolar depression, 250–252
- vabacaserin, 159  
 Valium (diazepam), 5
- valproate, 341, 372–373, 384, 386  
 for mild mania, 383  
 in combinations of mood stabilizers, 383  
 mood-stabilizing properties, 373–375  
 possible mechanisms of action, 373–374  
 possible side effects in women, 385  
 side effects, 375  
 valproate sodium. *See* valproate.  
 valproic acid. *See* valproate.  
 varenicline, 385, 500, 549–551  
 vascular dementia, 504  
 cognitive symptoms, 85  
 vasomotor symptoms  
 in perimenopausal women, 307–308  
 vasopressin 1B antagonists, 365  
 venlafaxine, 48, 304  
 extended-release formulation, 307  
 properties, 306–307  
 venlafaxine XR, 307  
 ventromedial prefrontal cortex (VMPFC), 122  
 in schizophrenia, 122–126  
 vesicular acetylcholine transporter (VAChT), 29, 34  
 vesicular glutamate transporters (VGLUT), 29, 34, 115  
 vesicular inhibitory amino acid transporters (VIAATs), 29, 34, 397  
 vesicular monoamine transporter 2 (VMAT2), 30, 86, 142, 258  
 vesicular monoamine transporters (VMATs), 29  
 vesicular neurotransmitter transporters, 29–32  
 proton pump mechanism, 34  
 SLC18 gene family targets for psychotropic drugs, 34  
 subtypes and functions, 33–34  
 vilazodone, 159, 300–302, 365, 405  
 violence  
 impulsive–compulsive behavior in psychiatric disorders, 574
- Vivactil, 342  
 vocational rehabilitation, 227  
 voltage-gated ion channels, 52  
 structure and function, 67–74  
 voltage-sensitive calcium channels (VSCCs), 9, 71–73  
 subtypes, 71–73  
 voltage-sensitive sodium channels (VSSCs), 9, 68–71  
 volume neurotransmission, 6–8  
 vortioxetine, 159, 162, 365, 500
- wake-promoting agents  
 amphetamine, 468  
 armodafinil, 468  
 caffeine, 469  
 gamma hydroxybutyrate (GHB), 468–470  
 methylphenidate, 468  
 modafinil, 466–468  
 sodium oxybate, 468–470  
 stimulants, 468  
 Xyrem, 468–470  
 weight loss treatment, 463  
 Wellbutrin, 298
- women  
 bipolar disorder and mood stabilizers, 385–386  
 possible side effects of valproate, 385
- Xanax (alprazolam), 5  
 Xyrem, 468–470
- Z-drugs, 341, 453–455, 559  
 zaleplon, 341, 453, 455  
 ziprasidone, 49–50, 159, 162, 171, 342  
 metabolic risk, 173  
 pharmacologic properties, 196–197  
 Zolof, 298  
 zolpidem, 341, 453–455  
 zonisamide, 384–385, 564, 571  
 zopiclone, 453–455  
 zotepine, 48–50, 171  
 pharmacologic properties, 190  
 zuclopenthixol, 131